Long-term study of bitopertin for EPP safety and benefit
Part of Digestive system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed EPP diagnosis and finished a prior bitopertin study phase (including the end-of-study visit)
- You are at least 12 years old when you sign up
- You meet the study’s body size limits (for under 18: at least 32 kg; for adults: BMI at least 18.5)
- If you could become pregnant (or your partner could), you must use very reliable birth control during the study and for at least 30 days after the last dose
- You can’t be pregnant (negative urine or blood pregnancy test if you could become pregnant)
- You must be able to follow study visits and instructions and sign consent (assent if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a standard surgery and chemotherapy plan for type I pleuropulmonary blastoma (PPB) to adding the drug topotecan for types II and III PPB. The goal is to see if the extra drug helps shrink tumors and improve outcomes for children with more advanced disease.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
This program provides access to bitopertin, an experimental medicine being tested for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—rare genetic conditions affecting how your body processes heme, a component of blood. The program aims to offer the medication to eligible patients while safety is being studied.
This trial checks the long-term safety and side effects of an oral medicine called dersimelagon in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). It is mainly for people who have already finished an earlier dersimelagon study and are able to keep coming to clinic visits.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
This trial is for people who have already taken part in an earlier study of the drug HB0034 for generalized pustular psoriasis (GPP). It checks how safe and effective the drug is over a longer period of time.
Hear when a new Erythropoietic Protoporphyria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.